CR IMO is better at this point in the business, less risk involved of not servicing the loan, if sales does not materialise within a reasonable timeframe. Also the register this is not huge so I don't see dilution as being an issue.
Djwally's original post around CR IMO summarised what is likely happening really well. If he is correct, then I think this shop is being run very well and we are unlikely to see a CR for a little while. When we do, it is either for a large order and/or significant ramp up of distribution costs after obtaining FDA. By that stage, if they don't do a CR, I'd be screaming at them to do one lol.
GLTAH
NTI Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
